Symbols

EVMN

Evommune·NYSE

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EVMN

Evommune, Inc.

A U.S.biotech company focused on diseases such as urticaria and atopic dermatitis,with tissue genetics as the core of its R&D,holding multiple clinical-stage therapies

Industry

Pharmaceutical

Established Date

Listing Date

11/06/2025

Exchange

New York Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.evommune.com

Security Type

Common stock

Office address

1841 Page Mill Road Suite 100 Palo Alto CA 94304

Business

Introduction

Evommune, Inc., a Delaware corporation incorporated in April 2020, is headquartered in Palo Alto, California. The company is a clinical-stage biotechnology company focused on the development of innovative treatments for the main pathogenic factors of chronic inflammatory diseases. Its initial clinical development projects focus on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis.

Company Financials

EPS

EVMN has released its 2025 Q3 earnings. EPS was reported at -8.07, versus the expected -11.35, beating expectations. The chart below visualizes how EVMN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EVMN has released its 2025 Q3 earnings report, with revenue of 10.00M, reflecting a YoY change of NaN%, and net profit of -12.47M, showing a YoY change of 21.62%. The Sankey diagram below clearly presents EVMN's revenue sources and cost distribution.